Lancaster JM - Search Results

1

Patterns of gene expression that characterize long-term survival in advanced stage serous ovarian cancers.

Berchuck A, Iversen ES, Lancaster JM, Pittman J, Luo J, Lee P, Murphy S, Dressman HK, Febbo PG, West M, Nevins JR, Marks JR. Berchuck A, et al. Among authors: lancaster jm. Clin Cancer Res. 2005 May 15;11(10):3686-96. doi: 10.1158/1078-0432.CCR-04-2398. Clin Cancer Res. 2005. PMID: 15897565

2

An inevitable dilemma: prenatal testing for mutations in the BRCA1 breast-ovarian cancer susceptibility gene.

Lancaster JM, Wiseman RW, Berchuck A. Lancaster JM, et al. Obstet Gynecol. 1996 Feb;87(2):306-9. doi: 10.1016/0029-7844(95)00405-X. Obstet Gynecol. 1996. PMID: 8559544

3

Detection of BRCA1 mutations in women with early-onset ovarian cancer by use of the protein truncation test.

Lancaster JM, Cochran CJ, Brownlee HA, Evans AC, Berchuck A, Futreal PA, Wiseman RW. Lancaster JM, et al. J Natl Cancer Inst. 1996 Apr 17;88(8):552-4. doi: 10.1093/jnci/88.8.552. J Natl Cancer Inst. 1996. PMID: 8606385 No abstract available.

4

BRCA2 mutations in primary breast and ovarian cancers.

Lancaster JM, Wooster R, Mangion J, Phelan CM, Cochran C, Gumbs C, Seal S, Barfoot R, Collins N, Bignell G, Patel S, Hamoudi R, Larsson C, Wiseman RW, Berchuck A, Iglehart JD, Marks JR, Ashworth A, Stratton MR, Futreal PA. Lancaster JM, et al. Nat Genet. 1996 Jun;13(2):238-40. doi: 10.1038/ng0696-238. Nat Genet. 1996. PMID: 8640235

5

Role of BRCA1 mutation screening in the management of familial ovarian cancer.

Berchuck A, Cirisano F, Lancaster JM, Schildkraut JM, Wiseman RW, Futreal A, Marks JR. Berchuck A, et al. Among authors: lancaster jm. Am J Obstet Gynecol. 1996 Sep;175(3 Pt 1):738-46. doi: 10.1053/ob.1996.v175.a74288. Am J Obstet Gynecol. 1996. PMID: 8828444 Review.

6

Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer.

Lancaster JM, Brownlee HA, Bell DA, Futreal PA, Marks JR, Berchuck A, Wiseman RW, Taylor JA. Lancaster JM, et al. Mol Carcinog. 1996 Nov;17(3):160-2. doi: 10.1002/(SICI)1098-2744(199611)17:3<160::AID-MC8>3.0.CO;2-J. Mol Carcinog. 1996. PMID: 8944076

7

Dideoxy fingerprinting assay for BRCA1 mutation analysis.

Lancaster JM, Berchuck A, Futreal PA, Wiseman RW. Lancaster JM, et al. Mol Carcinog. 1997 Jul;19(3):176-9. Mol Carcinog. 1997. PMID: 9254884

8

Familial breast-ovarian cancer syndromes: BRCA1 and BRCA2.

Berchuck A, Carney M, Lancaster JM, Marks J, Futreal AP. Berchuck A, et al. Among authors: lancaster jm. Clin Obstet Gynecol. 1998 Mar;41(1):157-66. doi: 10.1097/00003081-199803000-00022. Clin Obstet Gynecol. 1998. PMID: 9504233 Review. No abstract available.

9

Progesterone receptor gene polymorphism and risk for breast and ovarian cancer.

Lancaster JM, Berchuck A, Carney ME, Wiseman R, Taylor JA. Lancaster JM, et al. Br J Cancer. 1998 Jul;78(2):277. doi: 10.1038/bjc.1998.480. Br J Cancer. 1998. PMID: 9683307 Free PMC article. No abstract available.

10

Aberrant splicing of the TSG101 tumor suppressor gene in human breast and ovarian cancers.

Carney ME, Maxwell GL, Lancaster JM, Gumbs C, Marks J, Berchuck A, Futreal PA. Carney ME, et al. Among authors: lancaster jm. J Soc Gynecol Investig. 1998 Sep-Oct;5(5):281-5. doi: 10.1016/s1071-5576(98)00018-5. J Soc Gynecol Investig. 1998. PMID: 9773405

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

133 results

Search Page